Brief news reports on Tuberculosis

Final hearing in TB drug patent case ends, verdict likely in a month

New Delhi: The Indian Patent Office had held its final hearing on a challenge filed by two tuberculosis survivors to prevent the Indian arm of drugmaker Johnson & Johnson from extending its patent on bedaquiline, used against drug-resistant TB, beyond the primary patent’s expiry in July.

Read More →

Study shows FDA-approved TB regimen may not work against the deadliest form of TB due to multidrug-resistant strains

Findings from a Johns Hopkins Children's Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB meningitis due to MDR strains.

Read More →

As with COVID-19, the effects of TB can linger long after it is cured

According to the World Health Organization, of the roughly 10 million people who fall ill with TB annually, over 80% survive, in most cases due to a six-month treatment course. Unfortunately, as with long COVID, being cured is not always the last hurdle and many people go on to struggle with post-TB lung disease.

Read More →

AI method shows promise for detecting active TB on X-ray

January 26, 2023 -- Researchers in India have developed a new artificial intelligence (AI) model for detecting active tuberculosis on chest x-rays, and they suggest that the approach offers significant potential for real-world applications in locations with limited resources.

Read More →

IJTLD February 2023 issue now online

The International Journal of Tuberculosis and Lung Disease (IJTLD) is the official publication of the International Union Against Tuberculosis and Lung Disease (The Union).

Read More →

Study finds TB vaccines cost-effective in lower-income countries

January 24, 2023 -- Harvard University researchers and collaborators conducted a modeling study that showed tuberculosis (TB) vaccination could be cost-effective in 73 of 105 (70%) low- and middle-income countries. The results, published on January 24 in PLOS Medicine, also predicted $474 billion in vaccine-related benefits by 2050.

Read More →

Mobile app comes in handy for healthcare workers as India chases target to reduce TB burden by 2025

Ahmedabad: A mobile application is helping bridge the gap in knowledge regarding tuberculosis for thousands of healthcare workers as the Central government strives to achieve its ambitious target to reduce the TB burden by 2025.

Read More →

Closing the gaps in TB detection — considerations for policy makers

Decentralised molecular testing for TB could reduce missed diagnoses and losses to follow-up in high-burden settings.

Read More →

Practical manual on TB laboratory strengthening, 2022 update


Read More →

Webinar: What's new in childhood TB

The Stop TB Partnership and partners will host a webinar on 26 January 2023, What's new in childhood TB.

Read More →

Page 1 of 828 · Total posts: 10

1 2 Last→